DGAP-News

Agennix AG Provides Strategic Update - Seite 2

clinical development programs include oral talactoferrin alfa; a topical
gel form of talactoferrin and RGB-286638, a multi-targeted kinase
inhibitor. Agennix's registered seat is in Heidelberg, Germany. The
Company's site of operation is in Princeton, New Jersey. For additional
information, please visit the Agennix website at www.agennix.com.

This press release contains forward-looking statements, which express the
current beliefs and expectations of the management of Agennix AG. Such
statements are based on current expectations and are subject to risks and
uncertainties, many of which are beyond our control, that could cause
future results, performance or achievements to differ significantly from
those expressed or implied by such forward-looking statements. Actual
results could differ materially depending on a number of factors, and we
caution investors not to place undue reliance on the forward-looking
statements contained in this press release. There can be no guarantee that
the Company will have or be able to obtain additional financial resources
to avoid insolvency or that it will be successful in pursuing a strategic
transaction. Forward-looking statements speak only as of the date on which
they are made and Agennix undertakes no obligation to update these
forward-looking statements, even if new information becomes available in
the future.

Agennix(R) is a trademark of Agennix AG.

For further information, please contact:


Barbara Mueller
Manager, Investor Relations & Corporate Communications
Phone: [phone]
[e-mail]


End of Corporate News

---------------------------------------------------------------------

09.04.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language: English
Company: Agennix AG
Im Neuenheimer Feld 515
69120 Heidelberg
Germany
Phone: [phone]
Fax: [phone]
E-mail: [e-mail]
Internet: www.agennix.com
ISIN: DE000A1A6XX4
WKN: A1A6XX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart


End of News DGAP News-Service
---------------------------------------------------------------------
206596 09.04.2013